|View printer-friendly version|
|April 25, 2004 5:02 p.m.|
|Teva Announces Tentative Approval Of Flumazenil Injection|
Jerusalem, Israel, April 25, 2004 - Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced today that the U.S. Food and Drug Administration has granted tentative approval for an ANDA for Flumazenil Injection, 0.1 mg/mL, which was submitted by the Company's subsidiary SICOR Inc. Final approval of this product is expected upon expiration of patent protection on October 10, 2004.